Keyphrases
Chagas Disease
74%
Protease Inhibitors
74%
Trypanosoma Cruzi (T. cruzi)
56%
Visceral Leishmaniasis
49%
Preclinical Candidate
49%
Pyridazinone
37%
Disubstituted piperazines
37%
Guided Synthesis
37%
Structure-based Design
37%
Scaffold Hopping
37%
1,4-Diazepines
37%
Medicinal Chemistry
25%
South America
24%
Parasitic Infection
24%
Metabolic Stability
18%
Bioisosteric Replacement
18%
Causative Agents
18%
Piperazine Ring
18%
Current Treatment
18%
Pharmacokinetic Profile
18%
Plate-like
18%
Medical Intervention
18%
Low Water Solubility
12%
Proteasome Inhibition
12%
Series Structure
12%
In Vivo Efficacy
12%
In Silico Profiling
12%
Costructure
12%
Structure-activity Relationship
12%
Absorption Distribution
12%
Leishmania
12%
Metabolism
12%
Central America
12%
Genotoxicity
12%
Drive Optimisation
12%
Efficacy Study
12%
Cryogenic Electron Microscopy
12%
Asia
12%
Cryo-EM Structure
12%
East Africa
12%
Phenotypic Screen
12%
Developable
12%
Benzodiazepinedione
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chagas Disease
100%
Trypanosoma Cruzi
93%
Proteasome Inhibitor
74%
Visceral Leishmaniasis
49%
Proteasome
49%
Structure Activity Relationship
49%
Piperazine Derivative
37%
Pharmaceutical Chemistry
37%
Cryo-Electron Microscopy
24%
Parasitosis
24%
Piperazine
18%
Pharmacokinetics
18%
Efficacy Study
12%
Leishmania
12%
Genotoxicity
12%
Drug Development
12%
Infection
12%
Neglected Disease
12%
Drug Discovery
12%
Antiparasitic Activity
12%
Protozoon
12%
Medicine and Dentistry
Proteasome Inhibitor
74%
Proteasome
49%
Visceral Leishmaniasis
49%
Trypanosoma Cruzi
37%
Chagas Disease
37%
Parasitic Disease
24%
Cryoelectron Microscopy
24%
Genotoxicity
12%
Leishmania
12%
Efficacy Study
12%
Structure-Activity Relationship
12%
In Silico
12%